Esperion (ESPR) announced that Otsuka Pharmaceutical, the Company’s partner in Japan for the development and commercialization of NEXLETOL tablets, received National Health Insurance Price Listing and launched NEXLETOL for the treatment of hypercholesterolemia and familial hypercholesterolemia. Under the terms of the collaboration and license agreement, Esperion will receive $90M in a near term payment as a result of the recent Otsuka achievements, including product and pricing approvals. The Company is also eligible to receive additional sales milestone payments based on total net sales achievements by Otsuka in Japan, as well as tiered royalties ranging from fifteen percent to thirty percent on net sales in Japan.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s Global Expansion and Strategic Advancements Drive Buy Rating
- Esperion says HLS received approval from Health Canada to market NILEMDO
- Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy
- Esperion announces new data from CLEAR outcomes on NEXLETOL
- Promising Clinical Data and Strong Market Presence Drive Buy Rating for Esperion